NCT04336189 - Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda | Biotech Hunter

Enrollment

2,757

Participants

Timeline

Start Date

December 28, 2020

Primary Completion Date

July 28, 2024

Study Completion Date

July 28, 2024

Conditions

Malaria

Interventions

DRUG

Sulfadoxine-pyrimethamine (SP)

SP (Kamsidar) will be supplied by Kampala Pharmaceutical Industries (KPI), Uganda. SP will be given as a single dose consisting of 3 full strength tablets.

DRUG

Dihydroartemisinin-piperaquine (DP)

DP (Duo-Cotecxin) will be supplied by Holley-Cotec, Beijing, China. DP will consist of 3 full strength tablets given once a day for 3 consecutive days.

Trial Locations (1)

Unknown

Infectious Diseases Research Collaboration Clinic - Masafu Hospital, Masafu

All Listed Sponsors

collaborator

National Institutes of Health (NIH)

NIH

collaborator

Infectious Diseases Research Collaboration, Uganda

OTHER

lead

Grant Dorsey, M.D, Ph.D.

OTHER